The Europe viscosupplementation market size was projected to be USD 4.49 billion in 2022. By the end of 2023, the market is likely to reach a valuation of USD 4.91 billion. The market for Europe viscosupplementation is expected to garner a 9.37% CAGR and reach a market worth USD 12.03 billion by 2033.
Key Market Trends and Highlights
| Attributes | Key insights |
|---|---|
| Estimated Market Value in 2022 | USD 4.49 billion |
| Expected Market Value in 2023 | USD 4.91 billion |
| Expected Market Value in 2033 | USD 12.03 billion |
| Value based CAGR from 2023 to 2033 | 9.37% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Report Attributes | Details |
|---|---|
| Market value in 2018 | USD 4.30 billion |
| Market value in 2022 | USD 4.49 billion |
| CAGR from 2018 to 2022 | 3.3% |
During the historical period, 2018 to 2022, the Europe viscosupplementation market grew at a CAGR of 3.3%. Healthcare organizations and pharmaceutical businesses launched awareness campaigns and educational activities to enlighten patients and healthcare professionals about the advantages and availability of viscosupplementation therapy.
Product formulas have improved due to the ongoing research and development efforts by manufacturers, including the creation of viscosupplements with greater longevity and efficacy. Viscosupplementation therapies become more appealing to patients and doctors due to these advancements.
The market grew due to the increasing skill of orthopedic experts in giving viscosupplementation injections and incorporating them into comprehensive treatment strategies.
Principal Consultant
The table below lists the top five nations expected to experience prominent growth during the forecast period. The United Kingdom and France are predicted to have the most development among these nations.
Forecast CAGRs from 2023 to 2033
| Countries | CAGR from 2023 to 2033 |
|---|---|
| The United Kingdom | 9.8% |
| France | 9.1% |
| Germany | 8.2% |
| Spain | 6.3% |
| Italy | 5.7% |
During the forecast period, the viscosupplementation market in the United Kingdom is expected to garner a 9.8% CAGR. The aging population in the United Kingdom and the rising incidence of osteoarthritis and other joint-related problems drives the need for viscosupplementation as a non-surgical therapy option.
Numerous viscosupplementation products have received regulatory approval in the United Kingdom, offering patients and medical professionals a variety of therapeutic alternatives.
The advanced healthcare system in the country, which includes specialist hospitals and clinics, makes it possible to administer viscosupplementation therapies effectively.
France market for viscosupplementation is likely to expand with a 9.1% CAGR from 2023 to 2033. Health tourism has taken up in the spa towns of France, known for their healing properties. Viscosupplementation therapies combined with pleasure and wellness activities draw patients from France and other countries to these cities, filling a distinct niche in the healthcare tourism industry.
In the field of medicine, France has a long history of research and invention. Government-sponsored research projects frequently investigate new viscosupplementation uses, formulations, and delivery techniques, expanding the range of therapeutic alternatives accessible to patients.
The Europe viscosupplementation market in Germany is likely to garner an 8.2% CAGR from 2023 to 2033. Patients from abroad seeking viscosupplementation along with other medical treatments are drawn to the well established health tourism sector of Germany. The country is a popular destination thanks to its advanced infrastructure and healthcare system.
In Germany, there is an increased prevalence of joint-related diseases such as osteoarthritis because of rising obesity rates. Germany is recognized for its orthopedic expertise and cutting-edge medical technology, which has increased demand for viscosupplementation for its minimally invasive treatment.
The Europe viscosupplementation market in Spain is anticipated to accelerate with a 6.3% CAGR during the forecast period. The favorable climate in Spain stimulates outdoor activities, rendering joint health a concern for its young population. This trend increases the demand for viscosupplementation among those who want to maintain an active lifestyle.
Like other European nations, Spain is undergoing a demographic change with a rise in older adults. This group frequently uses viscosupplementation to control joint discomfort and maintain mobility as they age. The private healthcare industry in Spain is vital in ensuring prompt access to viscosupplementation operations. Patients frequently seek therapy at private clinics if they need pain relief right away.
The Italy viscosupplementation market is poised to expand with a 5.7% CAGR during the forecast period. The importance of health and wellbeing in Italian culture is quite significant. Italian patients actively seek therapies like viscosupplementation to maintain joint health and lead active lives far into their senior years.
Viscosupplementation is a less invasive approach for treating osteoarthritis and associated problems, according to the highly qualified orthopedic specialists of Italy. The orthopedic expertise of the nation helps the market expand.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The table below highlights how the single injection viscosupplementation of Europe viscosupplementation market is projected to lead the regional market by product type. This segment is expected to garner an 8.2% CAGR during the forecast period.
The viscosupplementation demand in Europe has been gaining immense traction in the hospitals in the last few years. During the forecast period, the hospitals segment is likely to expand with a 7.9% CAGR.
| Category | CAGR from 2023 to 2033 |
|---|---|
| Single Injection Viscosupplementation | 8.2% |
| Hospitals | 7.9% |
Since more people are becoming aware of the need to regenerate articular joint cartilage, the single injection segment is anticipated to have a leading position in the Europe viscosupplementation industry over the projected period.
Patients will feel less pain if they receive fewer shots. A single injection is a popular choice because of how straightforward and minimally uncomfortable it is for most people. Single-injection viscosupplements frequently offer quicker relief from joint pain and stiffness than multi-injection regimens. Patients looking for immediate symptom alleviation may find this rapid onset intriguing.
In 2021, SEIKAGAKU CORPORATION (via TCM Biotech International Corp.) announced the introduction of HyLink, an intra-articular single-injection viscosupplement for treating knee osteoarthritis, in Taiwan. A cross-linked hyaluronate hydrogel, produced with the specialized cross-linking technology of Seikagaku, serves as the primary component of HyLink. Such factors aided the business in diversifying its product offering.
Based on the end user, the hospital segment is anticipated to take up a significant regional market share. The hospital segment is expected to experience a 7.9% CAGR during the forecast period.
Hospitals offer cutting-edge medical infrastructure and tools, which are crucial for safely and successfully providing viscosupplementation injections. Sterile environments, diagnostic equipment, and, if required, surgical facilities are all part of this infrastructure.
Orthopedic departments and competent healthcare specialists, such as orthopedic surgeons and rheumatologists, are common in hospitals. Hospitals are a popular location for viscosupplementation operations since these professionals are skilled in diagnosing and treating joint-related problems.
The need for cryotherapy technologies is anticipated to increase in the Europe region as a result of major manufacturers using cutting-edge technology in their viscosupplementation production. Some of the prominent developments by the important companies in this domain are provided below.
| Company | Key Developments |
|---|---|
| Anika Therapeutics, Inc. |
|
| Sanofi S.A. |
|
| Juniper Biologics |
|
| Attribute | Details |
|---|---|
| Projected market value in 2023 | USD 4.91 billion |
| Projected market value in 2033 | USD 12.03 billion |
| Forecast CAGR from 2023 to 2033 | 5.8% |
| Forecast period | 2023 to 2033 |
| Historical period | 2018 to 2022 |
| Market analysis | Value in USD billion |
| Key Regions Covered | Western Europe; Eastern Europe |
| Key Countries Profiled | The United Kingdom, France, Germany, Spain, Italy, Nordics, Russia |
| Key market segments | Product, End user, Region |
| Key companies profiled | Anika Therapeutics Inc.; Sanofi S.A.; Zimmer Biomet Holdings; Meda AB; Ferring B.V; Fidia Pharmaceutici S.p.A; Bioventus LLC; Teva Pharmaceutical Industries Ltd.; VIRCHOW BIOTECH; Lifecore Biomedical |
The Europe viscosupplementation market is expected to reach USD 4.91 billion by 2023.
The Europe viscosupplementation market is set to expand by a CAGR of 9.37% by 2033.
The Europe viscosupplementation industry is forecast to reach USD 12.03 billion by 2033.
A CAGR of 8.2% is anticipated for single injection viscosupplementation throughout the predicted period.
The hospitals sector is anticipated to grow at a 7.9% CAGR during the projected period.
1. Executive Summary 2. Market Overview 3. Market Background 4. Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product Type 5.1. Single Injection Viscosupplementation 5.2. Three Injection Viscosupplementation 5.3. Five Injection Viscosupplementation 6. Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 6.1. Hospitals 6.2. Ambulatory Surgical Centres 6.3. Orthopaedic Clinics 7. Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Western Europe 7.2. Eastern Europe 8. Western Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Eastern Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Market Structure Analysis 11. Competition Analysis 11.1. Anika Therapeutics Inc. 11.2. Sanofi S.A. 11.3. Zimmer Biomet Holdings 11.4. Meda AB 11.5. Ferring B.V 11.6. Fidia Pharmaceutici S.p.A 11.7. Bioventus LLC 11.8. Teva Pharmaceutical Industries Ltd. 11.9. VIRCHOW BIOTECH 11.10. Lifecore Biomedical 12. Assumptions & Acronyms Used 13. Research Methodology
Explore Healthcare Insights
View Reports
Europe Viscosupplementation Market
